Piton Therapeutics
Piton Therapeutics is an AI-enabled precision medicine biotech company focused on developing small molecule therapeutics for complex diseases, primarily targeting the gut microbiome. Their proprietary Fathom Platform integrates AI, multiomics, and systems biology to discover and develop highly selective, mechanism-based treatments for conditions such as Ulcerative Colitis, Autism Spectrum Disorder, and Type 2 Diabetes. Unlike microbiome companies focused on live bacteria, Piton develops single-molecule, single-mechanism therapeutics. Their approach for Ulcerative Colitis targets a cause of the disease for a significant patient sub-type, aiming for remission without immune compromise. For Autism Spectrum Disorder, their lead candidate shows promise in improving socialization and reducing anxiety in animal models. Piton's strategy for Type 2 Diabetes targets both human and microbial pathways to lower blood glucose levels. The company is advancing its lead programs toward IND-enabling stages, with a focus on delivering transformative patient outcomes.
Piton Therapeutics
Piton Therapeutics is an AI-enabled precision medicine biotech company focused on developing small molecule therapeutics for complex diseases, primarily targeting the gut microbiome. Their proprietary Fathom Platform integrates AI, multiomics, and systems biology to discover and develop highly selective, mechanism-based treatments for conditions such as Ulcerative Colitis, Autism Spectrum Disorder, and Type 2 Diabetes. Unlike microbiome companies focused on live bacteria, Piton develops single-molecule, single-mechanism therapeutics. Their approach for Ulcerative Colitis targets a cause of the disease for a significant patient sub-type, aiming for remission without immune compromise. For Autism Spectrum Disorder, their lead candidate shows promise in improving socialization and reducing anxiety in animal models. Piton's strategy for Type 2 Diabetes targets both human and microbial pathways to lower blood glucose levels. The company is advancing its lead programs toward IND-enabling stages, with a focus on delivering transformative patient outcomes.